

RESEARCH ARTICLE

Open Access

# New lanostane-type triterpene acids from *wolfiporia extensa*

Gaimei She<sup>†</sup>, Nailiang Zhu<sup>†</sup>, Shuai Wang, Yang Liu, Yinying Ba, Changqing Sun and Renbing Shi\*

## Abstract

**Background:** Dried sclerotia of *Wolfiporia extensa* (Polyporaceae) is used to invigorate the spleen and to tranquilize the mind in Chinese herbal medicine. Lanostane-type triterpene acids were regarded as major secondary metabolites from dried sclerotia of *W. extensa*.

**Results:** Three new lanostane-type triterpene acids, 3-*epi*-benzoyloxy-dehydrotumulosic acid (**1**), 3-*epi*-(3'-*O*-methyl malonyloxy)-dehydrotumulosic acid (**2**) and 3-*epi*-(3'-hydroxy-3'-methylglutaryloxy)-dehydrotumulosic acid (**3**), were isolated from the sclerotia of *W. extensa*, together with 3 known lanostane derivatives (**4–6**). Their structures were elucidated on the basis of spectroscopic analysis, including 1D and 2D-NMR techniques.

**Conclusion:** Six lanostane derivatives including three new triterpene acids and three known compounds were reported from the sclerotia of *W. extensa* in this paper.

## Background

Dried sclerotia of *Wolfiporia extensa* (Polyporaceae), well known as 'Fu-Ling' in China, is used to invigorate the spleen and to tranquilize the mind in Chinese herb medicine [1]. In combination with some other herbs, it shows activities as diuretic, sedative and analgesic [2]. Lanostane-type triterpenes were reported as major secondary metabolites, which are characterized with hydroxyl groups at C-16 position, and with a C-21 carboxylic acid group. A number of lanostane-type triterpene acids have been reported from dried sclerotia of *W. extensa*, in which some lanostane derivatives showed activities in the anti-tumor, anti-inflammatory and anti-oxidant activities [3-9]. As part of our continuing research on chemical constituents from Traditional Chinese Medicine (TCM) [10-12], three new lanostane-type triterpene acids, 3-*epi*-benzoyloxy-dehydrotumulosic acid (**1**), 3-*epi*-(3'-*O*-methyl malonyloxy)-dehydrotumulosic acid (**2**) and 3-*epi*-(3'-hydroxy-3'-methylglutaryloxy)-dehydrotumulosic acid (**3**) were isolated from the dried sclerotia of *W. extensa*, together with three known lanostane derivatives (**4–6**) (Figure 1). Here we report the structure elucidation of the new compounds as follows.

## Results and discussion


The dried sclerotia of *W. extensa* were extracted with 95% ethanol as described in Experimental part. The ethanolic extract was concentrated under reduced pressure to small volume and the solution was fractionated with a HPD-826 macroporous adsorptive resin column eluting with H<sub>2</sub>O and 90% EtOH. The 90% EtOH fraction was concentrated and repeatedly fractionated on reverse-phase ODS, and on silica gel column to obtain six lanostane-type triterpene acids (**1–6**). Of them, **4–6** were identified as known compounds, dehydropachymic acid (**4**) [7], dehydrotumulosic acid (**5**) [13] and 3-*epi*-dehydrotumulosic acid (**6**) [13] (Figure 1) by spectroscopic methods and comparison with reported data. Compounds **1–3** were identified as new compounds based on a detailed analysis of NMR as described below (Tables 1 and 2).

Compound **1** was obtained as a colourless crystal in CH<sub>3</sub>OH. The molecular formula was determined as C<sub>38</sub>H<sub>52</sub>O<sub>5</sub> from its positive HRESI-MS ([M + H]<sup>+</sup>, *m/z* 589.3864) and <sup>13</sup>C-NMR spectrum. The UV spectrum showed absorption at 234 nm, indicating the presence of a Δ<sup>7,9(11)</sup> diene moiety, which was further supported by an absorption band at 1641 cm<sup>-1</sup> in the IR spectrum. Strong IR absorption at 3400 and 1710 cm<sup>-1</sup> indicated the carboxyl group in **1** [13]. The <sup>1</sup>H-NMR spectrum of **1** showed signals from two secondary methyls (δ 0.97 and 0.99, each 3 H, d, *J* = 6.8 Hz), five tertiary methyls (δ 0.92, 0.95, 1.04,

\* Correspondence: shirb@126.com

<sup>†</sup>Equal contributors

School of Chinese Pharmacy, Beijing University of Chinese Medicine, No. 6, Zhonghuan South Road, Wangjing District, Beijing 100102, People's Republic of China



**Figure 1** Structure of compounds 1–6.

1.06 and 1.48, each 3 H, s), two oxygen-bearing methylenes [ $\delta$  4.52 (1 H, t,  $J=6.8$  Hz) and  $\delta$  5.09 (1 H, br s)], one terminal methylene group at  $\delta$  4.84 (1 H, s) and 4.97 (1 H, s), two olefinic methylenes at [ $\delta$  5.39 (1 H, d,  $J=5.6$  Hz) and  $\delta$  5.64 (1 H, br s)], together with signals from typical benzoyl group [ $\delta$  8.18 (2 H, d,  $J=7.2$  Hz), 7.35 (2 H, d,  $J=7.6$  Hz), 7.46 (1 H, t,  $J=7.4$  Hz)] (Table 1).  $^{13}$ C-NMR and DEPT spectra of **1** showed signals from 38 carbons, including one carboxyl carbon [ $\delta$  178.6 (C-21)], two carbons from terminal methylene group [ $\delta$  107.0 (C-31) and 156.1 (C-24)], four olefinic carbons [ $\delta$  116.7 (C-11), 120.8 (C-7), 142.9 (C-8) and 146.0 (C-9)], two oxygenated methylenes [ $\delta$  79.0 (C-3) and 76.4 (C-16)], seven methyl carbons [ $\delta$  17.6 (C-18), 21.9 (C-27), 22.0 (C-26), 22.4 (C-29), 22.7 (C-19), 26.6 (C-30) and 28.1 (C-28)], signals from benzoyl group [ $\delta$  165.9 (C-7'), 133.2 (C-4'), 131.4 (C-1'), 129.8 (C-2', 6'), and 128.9 (C-3', 5')], and signals from other fifteen carbons (see Table 2). The aforementioned NMR features were similar to those of 3-*epi*-dehydrotumulosic acid (**6**), except for the existence of an additional set of signals arising from the benzoyl group in **1** [13].

The downfield shift at C-3 ( $\delta$  79.0) in **1**, from ( $\delta$  75.1) in **6**, suggested that the additional benzoyl group was linked to C-3 position of dehydrotumulosic acid moiety. It was further confirmed by the HMBC experiment which showed correlation between H-3 ( $\delta$  5.09) with the signal from C-7' ( $\delta$  165.9) of the benzoyl groups.

The relative configuration was established by  $^1$ H-NMR and the NOESY experiment, in which the H-3 appeared as a broad singlet, the NOESY correlations of H-3 $\beta$  at ( $\delta$  5.09, 1 H, br s) with Me-29 $\beta$  at ( $\delta$  0.95, 3 H, s) revealed the

benzoyl linked the  $\alpha$  position of C-3 in compound **1**. On the basis of the above evidence, the structure of **1** was elucidated as 3 $\alpha$ -benzoyl-16 $\alpha$ -dihydroxy-lanost-7, 9(11), 24(31)-trien-21-oic acid, named as 3-*epi*-benzoyloxyl-dehydrotumulosic acid.

Compound **2** was obtained as a colourless needle in CH<sub>3</sub>OH. Careful comparison of  $^{13}$ C-NMR spectra of **1** and **2** indicate that both have a similar lanostane skeleton with different substitution group (details in Table 2). Unlike compound **1** with a benzoyl group, compound **2** showed signals from a malonyl group [ $\delta$  41.9 (–CH<sub>2</sub>–), 166.4 (–COO–) and 167.6 (–COO–)] and a methoxyl group [ $\delta$  52.2 (–OCH<sub>3</sub>)]. HMBC experiment showed correlations between methoxyl proton ( $\delta$  3.63) with 3'-C ( $\delta$  166.4, from malonyl group) indicated the methyl malonate group [14]. The HMBC experiment of **2** revealed the correlation between H-3 ( $\delta$  4.86) and C-1' ( $\delta$  167.6), indicated the 3-substitution. Thus, compound **2** was established as 3- $\alpha$ -methyl-malonyl-16 $\alpha$ -dihydroxy-lanost-7, 9(11), 24(31)-trien-21-oic acid, named as 3-*epi*-(3'-O-methyl malonyloxy)-dehydrotumulosic acid.

The  $^{13}$ C-NMR spectra of **3** showed signals from a lanostane skeleton similar to those of **1** and **2** (Table 2), except with different substitution groups. Except signals from lanostane skeleton in compound **3**,  $^1$ H-NMR showed signals at [ $\delta$  3.12 (1 H, d,  $J=15.2$  Hz, H-2'), 3.16 (1 H, d,  $J=15.2$  Hz, H-2'), 3.02 (1 H, d,  $J=14.4$  Hz, H-4'), 3.08 (1 H, d,  $J=14.4$  Hz, H-4') and 1.71 (3 H, s, –CH<sub>3</sub>)] along with  $^{13}$ C-NMR showed signals [ $\delta$  171.4 (C-1'), 46.3 (C-2'), 69.9 (C-3'), 46.4 (C-4'), 174.6 (C-5'), and 28.4 (–CH<sub>3</sub>)]. Those signals were assigned to 3-hydroxy-3-methylglutaryl group based on HMQC and HMBC spectra data. It was further confirmed from ESI-MS experiment, which showed fragment ions at  $m/z$  525.4 [M-H-102 (CH (CH<sub>3</sub>) (OH)-CH<sub>2</sub>-COOH)]<sup>-</sup>. The HMBC correlations of H-3 ( $\delta$  4.94 br s) with C-1' ( $\delta$  171.4) confirmed that the 3-hydroxy-3-methylglutaryloxy group was at C-3 in **3** (Figure 1). The compound **3** is levorotatory. The *R*-configurations of C(3') in **3** was deduced by comparing of the compound **3** specific rotation features with those of (+)-3-*epi*-dehydrotumulosic acid, and (3' *S*)-(+)-3-hydroxy-3-methylglutamic acid, which are dextrorotatory [8,13]. These evidences indicated *R*-configuration of C(3') in compound **3**. As stated above, the structure of **3** was indicated as 3- $\alpha$ -(3'-hydroxy-3'-methylglutaryloxy)-16 $\alpha$ -dihydroxy-lanost-7, 9(11), 24(31)-trien-21-oic acid, named as 3-*epi*-(3'-hydroxy-3'-methylglutaryloxy)-dehydrotumulosic acid.

## Experimental

### General experimental procedures

Optical rotations were measured on a P-1020 Polarimeter (JASCO, Tokyo, Japan). UV spectra were obtained on a UV 210A Shimadzu spectrometer. IR spectra were recorded on an FT-IR spectrometer (Nicolet iS10, Thermo Scientifi,

**Table 1 <sup>1</sup>H-NMR data of 1–3 (at 500 or 600 MHz, in C<sub>5</sub>D<sub>5</sub>N; δ in ppm, J in Hz)**

position	1	2	3
1	1.73, m 1.82, td (9.6, 3.2)	1.65, m 1.75, dd (13.8, 3.0)	1.69, m 1.88, m
2	1.91, m 1.97, m	1.79, dt (6.6, 3.0) 1.85, d (12.0)	1.78, ddd (15.6, 6.4, 2.8) 1.86, m
3	5.09, br s	4.86, br s	4.94, br s
5	1.88, dd (10.0, 4.0)	1.68, t (5.1)	1.76, dd (9.2, 6.4)
6	2.08, m 2.09, m	2.00, m 2.01, m	2.02, m 2.03, m
7	5.64, br s	5.57, br s	5.57, br s
11	5.39, d (5.6)	5.38, d (6.0)	5.39, d (6.0)
12	2.42, dd (15.6, 5.2) 2.66, d (16.8)	2.42, dd (18.0, 6.6) 2.66, d (18.0)	2.42, dd (17.2, 6.8) 2.66, d (16.4)
15	1.95, d (12.4) 2.47, dd (12.8, 9.2)	1.91, d (13.2) 2.45, t (3.9)	1.91, m 2.45, dd (12.4, 8.8)
16	4.52, t (6.8)	4.51, t (7.2)	4.52, t (6.8)
17	2.86, dd (11.2, 5.6)	2.85, dd (11.4, 6.0)	2.84, dd (11.2, 5.6)
18	1.06, s	1.05, s	1.04, s
19	1.04, s	0.99, s	1.00, s
20	2.95, td (10.8, 2.4)	2.94, dd (10.8, 3.0)	2.92, td (10.8, 2.0)
22	2.46, m 2.68, m	2.51, m 2.63, m	2.42, m 2.61, m
23	2.37, m 2.55, br d (11.6)	2.38, m 2.54, m	2.38, m 2.54, m
25	2.29, m	2.29, m	2.27, m
26	0.97, d (6.8)	0.97, d (6.6)	0.97, d (6.8)
27	0.99, d (6.8)	0.98, d (6.6)	0.99, d (6.8)
28	0.92, s	0.87, s	0.90, s
29	0.95, s	0.90, s	0.96, s
30	1.48, s	1.42, s	1.41, s
31	4.84, br s 4.97, br s	4.83, br s 4.97, br s	4.83, br s 4.96, br s
2'	8.18, d (7.2)	3.60, s	3.12, d (15.2) 3.16, d (15.2)
3'	7.35, t (7.6)	–	–
4'	7.46, t (7.4)	3.63, s	3.02, d (14.4) 3.08, d (14.4)
5'	7.35, t (7.6)	–	–
6'	8.18, d (7.2)	–	–
-CH <sub>3</sub>	–	–	1.71, s

USA) with KBr pellets. <sup>1</sup>H- and <sup>13</sup>C-NMR spectrum was recorded in pyridine-*d*<sub>5</sub> with Bruker AM-400, DRX-500 and VARIAN INOVA-600 spectrometers operating at 400, 500 and 600 MHz for <sup>1</sup>H-NMR experiments, and 125 and 150 MHz for <sup>13</sup>C-NMR experiment, respectively. Coupling constants are expressed in Hertz (Hz) and chemical shifts are given on a δ (ppm) scale with tetramethylsilane as internal standard. Negative ion ESI-MS and HRESI-MS

were recorded on an AutoSpec 3000 spectrometer (VG, Manchester, UK). Column chromatography separations were performed using HPD-826 (Cangzhou Bon Adsorber Technology Co., Cangzhou, China), Chromatorex ODS

**Table 2 <sup>13</sup>C-NMR Data of 1–3 (at 125 or 150 MHz, in C<sub>5</sub>D<sub>5</sub>N; δ in ppm)**

Position	1	2	3
1	31.2	30.8	31.1
2	23.5	23.2	23.4
3	79.0	79.6	78.2
4	37.7	36.8	36.7
5	45.3	44.7	44.8
6	23.2	23.1	23.1
7	120.8	120.8	120.7
8	142.9	142.7	142.8
9	146.0	146.0	146.0
10	37.2	37.6	37.6
11	116.7	116.6	116.5
12	36.2	36.2	36.2
13	45.1	45.1	45.1
14	49.5	49.5	49.5
15	44.4	44.4	44.4
16	76.4	76.4	76.4
17	57.6	57.6	57.6
18	17.6	17.6	17.6
19	22.7	22.6	22.7
20	48.5	48.5	48.5
21	178.6	178.7	178.6
22	31.4	31.4	31.4
23	33.2	33.2	33.2
24	156.1	156.0	156.1
25	34.1	34.1	34.1
26	22.0	22.0	22.0
27	21.9	21.8	21.8
28	28.1	27.9	28.1
29	22.4	22.3	22.5
30	26.6	26.6	26.6
31	107.0	107.0	107.2
1'	131.4	167.6	171.4
2'	129.8	41.9	46.3
3'	128.9	166.4	69.9
4'	133.2	52.2	46.4
5'	128.9	–	174.6
6'	129.8	–	–
7'	165.9	–	–
3'-Me	–	–	28.4

(Fuji Silysia Chemical Co., Greenville, USA) and Silica gel (Qingdao Haiyang Chemical Co., Qingdao, China) as adsorbants. TLC was carried on silica gel G precoated plates (Qingdao Haiyang Chemical Co., Qingdao, China). The TLC plate was monitored by spraying with 10% H<sub>2</sub>SO<sub>4</sub> solution in ethanol followed by heating.

#### Fungal material

The dried sclerotia of *W. extensa* were collected from Hebei Guang Ming Prepared Medicinal Herbs Co., Ltd, China and identified by Prof. Yu-Ting Cheng (Beijing University of Chinese Medicines). An authentic sample was kept in School of Chinese Pharmacy, Beijing University of Chinese Medicines.

#### Extraction and isolation

The dried sclerotia of *W. extensa* (17.5 kg) were powdered and extracted with exhaustively 95% EtOH under reflux. The EtOH extract was concentrated to the small volume (3 L), and applied on a HPD-826 macroporous adsorptive resin (15 Kg, 18 cm × 150 cm), eluting with H<sub>2</sub>O (60 L) and 90% EtOH (80 L). The 90% EtOH fraction was concentrated under reduced pressure, and the residue (60 g) was subjected to column chromatography (CC) on silica gel eluted with CHCl<sub>3</sub>/CH<sub>3</sub>OH (4:1 to 1:1, 5 L) to obtain eight fractions (Fr 1–Fr 8). Fr 1, was further fractionated on silica gel eluted with cyclohexane/CHCl<sub>3</sub> (8:1 and 4:1, each 1 L), and ODS eluted with a step gradient of H<sub>2</sub>O/MeOH (1:0 → 0:1), and PTLC (Cyclohexane/CHCl<sub>3</sub>/HOAc, 3:1:0.1) to give **1** (20 mg), **2** (10 mg) and **4** (10 mg). Fraction 2 was fractionated repeatedly on Silica gel (CHCl<sub>3</sub>/EtOAc, 8:1) and ODS (CH<sub>3</sub>OH/H<sub>2</sub>O, 75:25 → 85:15), eluted with CHCl<sub>3</sub>/CH<sub>3</sub>OH (50:1), to obtain **5** (20 mg) and **6** (10 mg) from Fr 2. Fr 3 was subjected to CC on silica gel (CHCl<sub>3</sub>/EtOAc, 4:1), and preparative TLC on silica gel (CHCl<sub>3</sub>/EtOAc/HOAc, 1:1:0.1) to obtain **3** (20 mg).

#### 3-epi-benzoyloxyl-dehydrotumulosic acid (1)

Colourless needles; <sup>1</sup>H-NMR (in pyridine-*d*<sub>5</sub>): see Table 1. <sup>13</sup>C-NMR (in pyridine-*d*<sub>5</sub>): see Table 2. IR (KBr) cm<sup>-1</sup>: 3400, 2928, 1710, 1641, 1279, 1175, 895, 800. UV λMeOH max nm (log): 234 (4.32). HRESI-MS (*m/z*): 589.3864 [M + H]<sup>+</sup>, calcd for C<sub>38</sub>H<sub>53</sub>O<sub>5</sub>, 589.3893. ESI-MS (*m/z*) (rel. int.): 587.3 [M - 1]<sup>-</sup> (100), 417.0 (23), 338.9 (4), 208.8 (13).

#### 3-epi-(3'-O-methyl malonyloxy)-dehydrotumulosic acid (2)

Colourless needles; <sup>1</sup>H-NMR (in pyridine-*d*<sub>5</sub>): see Table 1. <sup>13</sup>C-NMR (in pyridine-*d*<sub>5</sub>): see Table 2. IR (KBr) cm<sup>-1</sup>: 3416, 2960, 1736, 1707, 1641, 1254, 1152, 891, 800. UV λMeOH max nm (log): 243 (4.16). HRESI-MS (*m/z*): 607.3605 [M + Na]<sup>+</sup>, calcd for C<sub>35</sub>H<sub>52</sub>O<sub>7</sub>Na, 607.3611.

#### 3-epi-(3'-hydroxy-3'-methylglutaryloxyl)-dehydrotumulosic acid (3)

Colourless needles; [α] = -7.6 (*c* = 0.1705, pyridine); <sup>1</sup>H-NMR (in pyridine-*d*<sub>5</sub>): see Table 1. <sup>13</sup>C-NMR (in pyridine-*d*<sub>5</sub>): see Table 2. IR (KBr) cm<sup>-1</sup>: 3389, 2962, 1707, 1642, 1205, 1176, 891, 802, 780, 770. UV λMeOH max nm (log): 244 (4.13); HRESI-MS (*m/z*): 651.3880 [M + Na]<sup>+</sup>, calcd for C<sub>37</sub>H<sub>56</sub>O<sub>8</sub>Na, 651.3873. ESI-MS (*m/z*) (rel. int.): 627.5 [M - 1]<sup>-</sup> (100), 525.4 (5).

#### Competing interests

The authors declare that they have no competing interests.

#### Authors' contributions

GS carried out the chemical analysis-structure elucidation and drafted the Manuscript; NZ carried out the chemical studies; SW employed in the several chemical assays of extraction and isolation; YL worked at the part of experimental design; YB engaged in the part of chemical analysis-structure elucidation; CS carried out the part of chemical assays of extraction and isolation; SR conceived of the study and its design and coordination of the scientific teams. All authors have read and approved the final manuscript.

#### Acknowledgements

This work was supported by Important National Science & Technology Specific Projects during the 11th Five-Year Plan Period (NO. 2009ZX09502-006), Innovative research team of Beijing University of Chinese Medicine (NO. 2011-CXTD-12), the Twelfth Five-Year National Science & Technology Support Program (NO. 2012BAI29B06), National Natural Science Foundation of China (NO. 81102776) and the Beijing Nova program (NO. 2011070).

Received: 13 January 2012 Accepted: 6 May 2012

Published: 6 May 2012

#### References

1. The Pharmacopoeia Commission of P.R.C: *Pharmacopoeia of People's Republic of China*. Beijing: Chemical Industry Press; 2010:224. ISBN 1.
2. Giner-Larza EM, Mánez S, Giner-Pons RM, Carmen RM, Ríos JL: On the anti-inflammatory and anti-phospholipase A2 activity of extracts from lanostane-rich species. *J Ethnopharmacology* 2000, **73**:61–69.
3. Ukiya M, Akihisa T: Inhibition of tumor-promoting effects by poricoic acids G and H and other lanostane-type triterpenes and cytotoxic activity of poricoic acids A and G from *Poria cocos*. *J Nat Prod* 2002, **65**:462–465.
4. Akihisa T, Nakamura Y, Tokuda H, Uchiyama E, Suzuki T, Kimura Y, Uchikura K, Nishino H: Triterpene acids from *Poria cocos* and their anti-tumor-promoting effects. *J Nat Prod* 2007, **70**:948–953.
5. Akihisa T, Uchiyama E, Kikuchi T, Tokuda H, Suzuki T, Kimura Y: Anti-tumor-promoting effects of 25-methoxyporicoic acid A and other triterpene acids from *Poria cocos*. *J Nat Prod* 2009, **72**:1786–1792.
6. Nukaya H, Yamashiro H, Fukazawa H, Ishida H, Tsuji K: Isolation of inhibitors of TPA-induced mouse ear edema from hoelen. *Poria cocos*. *Chem Pharm Bull* 1996, **44**:847.
7. Yasukawa K, Kaminaga T, Kitanaka S, Tai T, Nunoura Y, Natori S, Takido M: 3β-p-Hydroxybenzoyldehydrotumulosic acid from *Poria cocos*, and its anti-inflammatory effect. *Phytochemistry* 1998, **48**:1357–1360.
8. Kamo T, Asanoma M, Shibata H, Hirota M: Anti-inflammatory lanostane-type triterpene acids from *Piptoporus betulinus*. *J Nat Prod* 2003, **66**:1104–1106.
9. Zhou L, Zhang YC, Gapter LA, Ling H, Agarwal R, Ng K: Cytotoxic and anti-oxidant activities of lanostane-type triterpenes isolated from *Poria cocos*. *Chem Pharm Bull* 2008, **56**:1459–1462.
10. She GM, Wang D, Zeng SF, Yang CR, Zhang YJ: New Phenylethanoid glycosides and sugar esters from Ku-Ding-Cha, a herbal tea produced from *Ligustrum purpurascens*. *J Food Sci* 2008, **73**:C476–C481.
11. She GM, Xu C, Liu B, Shi RB: Polyphenolic acids from mint (the aerial of *Mentha haplocalyx* Briq.) with DPPH Radical Scavenging Activity. *J Food Sci* 2010, **75**:C359–C362.
12. She GM, Xu C, Liu B, Shi RB: Two new monoterpenes from *Mentha haplocalyx* Briq. *Helv Chim Acta* 2010, **93**:2495–2498.

13. Tai T, Shingu T, Kikuchi T, Tezuka Y, Akahori A: **Triterpenes from the surface layer of *Poria cocos***. *Phytochemistry* 1995, **39**:1165–1169.
14. Kemami WHV, Berg A, Hertel W, Nkengfack AE, Heartweck C: **Anti-inflammatory and anti-hyaluronate lyase activities of lanostanoids from *Piptoporus betulinus***. *J Antibiot* 2004, **57**:755–758.

doi:10.1186/1752-153X-6-39

**Cite this article as:** She et al.: New lanostane-type triterpene acids from *wolfiporia extensa*. *Chemistry Central Journal* 2012 **6**:39.

Publish with **ChemistryCentral** and every scientist can read your work free of charge

*“Open access provides opportunities to our colleagues in other parts of the globe, by allowing anyone to view the content free of charge.”*

W. Jeffery Hurst, The Hershey Company.

- available free of charge to the entire scientific community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
<http://www.chemistrycentral.com/manuscript/>



**ChemistryCentral**